Adverse Effects of Angiotensin-Converting Enzyme Inhibitors in Humans: A Systematic Review and Meta-Analysis of 378 Randomized Controlled Trials

Abstract

Background: Although angiotensin-converting enzyme (ACE) inhibitors are among the most-prescribed medications in the world, the extent to which they increase the risk of adverse effects remains uncertain. This study aimed to systematically determine the adverse effects of ACE inhibitors versus placebo across a wide range of therapeutic settings. Methods: Systematic searches were conducted on PubMed, Web of Science, and Cochrane Library databases. Randomized controlled trials (RCTs) comparing an ACE inhibitor to a placebo were retrieved. The relative risk (RR) and its 95% confidence interval (95% CI) were utilized as a summary effect measure. A random-effects model was used to calculate pooled-effect estimates. Results: A total of 378 RCTs fulfilled the eligibility criteria, with 257 RCTs included in the meta-analysis. Compared with a placebo, ACE inhibitors were associated with an significantly increased risk of dry cough (RR = 2.66, 95% CI = 2.20 to 3.20, p < 0.001), hypotension (RR = 1.98, 95% CI = 1.66 to 2.35, p < 0.001), dizziness (RR = 1.46, 95% CI = 1.26 to 1.70, p < 0.001), and hyperkalemia (RR = 1.24, 95% CI = 1.01 to 1.52, p = 0.037). The risk difference was quantified to be 0.037, 0.030, 0.017, and 0.009, respectively. Conclusions: We quantified the relative risk of numerous adverse events associated with the use of ACE inhibitors in a variety of demographics. This information can help healthcare providers be fully informed about any potential adverse consequences and make appropriate suggestions for their patients requiring ACE inhibitor therapy.

Comprehensive Multimorbidity Patterns in Older Patients Are Associated with Quality Indicators of Medication—MoPIM Cohort Study

“…Conversely, angiotensin receptor blockers caused ADRs in a higher proportion of patients in the minor chronic disease cluster but were not labelled as inappropriately prescribed. Our results, therefore, suggest that, although side effects of antihypertensive drugs are well-known [ 49 , 50 , 51 ], decompensations particularly occur in these patients and may lead to life-threatening situations, which were consistently found to be higher in both clusters. However, these situations may be harder to address, as they might not always be identified as PIMs.…”

Exploring peptidomes of by-products generated during chhurpi production using Lactobacillus delbrueckii WS4 for identification of novel bioactive peptides

“…30 However, the antihypertensive potency of these drugs is overshadowed by several reported adverse effects including hypotension, weakened immune system, and organ failure. 31 Thus, there is a need to shift hypertension treatment by employing natural ACE inhibitors that are devoid of side effects. Soy whey showed a significantly elevated ( p < 0.05) ACE inhibition when compared to whey, and thus, its in vitro activity was evaluated using a sample amount of 100 mg ml −1 for whey and 5 mg ml −1 for soy whey (Fig.…”

Potential antihypertensive activity of novel peptides from green basil leaves

“…Captopril is taken with an empty stomach. Lisinopril tends to more effective in patients compared to captopril [ 31 ]. Thus, these drugs were chosen as positive controls in the present study’s in vitro and in vivo investigations.…”